Thu Sep 19 06:58:52 UTC 2024: ## Verona Pharma (VRNA) Stock Receives “Buy” Rating from HC Wainwright

**New York, NY – September 19, 2024** – Verona Pharma (NASDAQ:VRNA), a clinical-stage biopharmaceutical company specializing in respiratory disease treatments, has been given a “Buy” rating by investment firm HC Wainwright. The firm also set a price target of $36.00 for the stock, representing a potential upside of 23.16% from its previous close.

This positive outlook follows a string of similar recommendations from other analysts. Truist Financial recently raised their price objective to $38.00 and maintained a “Buy” rating, while Canaccord Genuity Group increased their target price to $37.00 and also reaffirmed a “Buy” rating. MarketBeat, a financial news aggregator, reports an average “Buy” rating for VRNA with a consensus price target of $36.00.

Despite missing earnings estimates in the most recent quarter, analysts remain optimistic about Verona Pharma’s future prospects. They anticipate the company will post -2.07 earnings per share for the current fiscal year.

Meanwhile, institutional investor interest in Verona Pharma continues to grow. CWM LLC, EMC Capital Management, Cape Investment Advisory Inc., Legato Capital Management LLC, and Marshall Wace LLP all purchased new stakes in the company during recent quarters.

Verona Pharma’s lead product candidate, ensifentrine, is an inhaled dual inhibitor of PDE3 and PDE4 enzymes, offering both bronchodilation and anti-inflammatory benefits in a single compound. Ensifentrine is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Investors and analysts alike seem to be enthusiastic about Verona Pharma’s potential to deliver groundbreaking treatments for respiratory diseases, contributing to the stock’s positive outlook.

Read More